A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)

NCT07261644

Status	RECRUITING
Phase	Phase 3
Sponsor	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Enrollment	500 participants

Key Eligibility Criteria

Inclusion (5)

- Able to understand and comply with the protocol requirements, participate and sign the informed consent form (ICF) voluntarily;
- At least 18 years of age at the time of signing the ICF, with no gender restrictions;
- Meet the 1984 modified New York criteria for ankylosing spondylitis (AS);
- Have inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) or have contraindications/intolerance to NSAIDs treatment;
- Willing to practice contraception and have no plans for pregnancy, sperm donation, or egg donation from the screening period until at least 6 months after the last dose.

Exclusion (5)

- Patients with other uncontrolled active inflammatory diseases.
- Clinical laboratory tests and other tests that reveal abnormalities with clinical significance
- Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.
- History of cancer.
- Known or suspected history of immunosuppression.

Locations (1 total)

Site 01, Beijing, Beijing Municipality, China